Humacyte, Inc. (NASDAQ:HUMA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Humacyte, Inc. (NASDAQ:HUMA) by 85.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 202,825 shares of the company’s stock after acquiring an additional 93,283 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of Humacyte worth $1,024,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HUMA. Woodline Partners LP lifted its holdings in Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock valued at $14,386,000 after acquiring an additional 2,000,268 shares during the period. CenterBook Partners LP acquired a new stake in Humacyte in the fourth quarter valued at $6,463,000. Brevan Howard Capital Management LP lifted its holdings in Humacyte by 2,795.1% in the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock valued at $4,426,000 after acquiring an additional 846,070 shares during the period. Vanguard Group Inc. increased its position in shares of Humacyte by 10.8% in the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after buying an additional 543,995 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new position in shares of Humacyte during the 4th quarter worth $2,189,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Trading Down 1.2%

Shares of HUMA stock opened at $2.56 on Tuesday. The firm has a 50-day moving average price of $1.81 and a 200 day moving average price of $3.19. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $9.79. The company has a market capitalization of $397.10 million, a price-to-earnings ratio of -1.91 and a beta of 2.00.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.46 million. As a group, research analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wall Street Zen raised Humacyte from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Monday. Benchmark cut their price target on Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Finally, HC Wainwright assumed coverage on Humacyte in a research note on Wednesday, May 14th. They set a “buy” rating and a $4.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.71.

Insider Activity at Humacyte

In other news, Director Kathleen Sebelius bought 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 8th. The stock was purchased at an average price of $1.32 per share, with a total value of $66,000.00. Following the purchase, the director now owns 91,207 shares of the company’s stock, valued at $120,393.24. This trade represents a 121.34% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Dale A. Sander purchased 20,000 shares of the stock in a transaction on Thursday, April 10th. The stock was acquired at an average price of $1.53 per share, with a total value of $30,600.00. Following the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at $62,118. This trade represents a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 83,993 shares of company stock valued at $118,224. 5.10% of the stock is owned by insiders.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.